Navigation Links
Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
Date:10/25/2011

PITTSBURGH and POTTERS BAR, England, Oct. 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.K.-based subsidiary has launched Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 mg and 6 mg. This product is the generic version of Novartis' Exelon® Capsules, a treatment for dementia in people with Alzheimer's disease. Mylan is the first company to launch a generic Rivastigmine formulation in the U.K.

Mylan Chairman and CEO Robert J. Coury said: "This is the second recent first-to-market generic for Mylan's business in the U.K., following the company's successful launch of Modafinil tablets, 100 mg, the generic version of Cephalon's Provigil®, earlier this year. We are excited to be adding generic Rivastigmine to our strong portfolio of more than 350 products in the U.K., and delivering on our brand's commitment of providing high quality and affordable medicines to patients around the world."

Rivastigmine Capsules POM had U.K. sales of approximately pounds Sterling 7.9 million for the last 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
2. Matrix Laboratories Completes Name Change to Mylan Laboratories
3. Mylan Announces Femcon® Fe Settlement Agreement
4. Mylan Announces Intention to Refinance Existing Secured Credit Facility
5. Mylan Comments on Death of Company Co-Founder and Former Chairman and CEO Milan "Mike" Puskar
6. Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
7. Mylan Announces XELODA® Settlement and License Agreement
8. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
9. Mylan Launches Generic Version of Uroxatral® Tablets
10. Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
11. Mylan Launches First Generic Version of Entocort EC® Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... CARLSBAD, Calif. , July 10, 2017  The ... in Boston, MA at the ... unequaled value and unparalleled access to global decision makers ... to draw 800+ life science leaders during two impactful ... Boston, and provides delegates with additional networking opportunities with ...
(Date:7/5/2017)... , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company focused ... that it has received approval from the Israel Securities Authority ... Exchange (TASE). Oramed common stock will commence trading on the ... on the current market capitalization of the Company, it is ...
(Date:6/30/2017)... 30, 2017 In vitro diagnostics market firm ... May, at least ten diagnostic companies have successfully completed ... offerings and a loan facility.  The size of these ... million.  Kalorama Information provides a monthly IVD Market ... Knowledge Center. ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been appointed ... part of Saint Luke’s Health System . Dr. Upadhyaya has served in the ... FAANS joins Stanley P. Fisher, M.D., who has served as medical co-director ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to the ... of Health Care Services, will facilitate the development of a hub and spoke ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... scholarship awards to be awarded annually to and divided between two full-time university ... bringing awareness to Amazonian plant medicine. To apply for the scholarship, students are ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider of ... with WALLIX to expand its solution to help government contractors more quickly ... number of ways to address the authentication requirements within NIST SP800-171, but no ...
(Date:7/24/2017)... ... ... A CDC study shows that, although people are taking more steps to protect themselves from ... least one case of sunburn within the past year. It’s common and people have been ... However, only recently have people become conscientious of the risks that accompany sunburns. , The ...
Breaking Medicine News(10 mins):